Transseptal versus left atrial approach for mitral valve surgery: A systematic review and meta-analysis.

Asian Cardiovasc Thorac AnnAug 12, 2026 (epub)
Clinical ResearchCardiothoracic Surgery

Sahithi Mc Paramkusam, Abhinav V Paramkusam, Bushra Abuzayed et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared transseptal (TS) and left atrial (LA) approaches for mitral valve surgery (MVS) across 25 studies. The TS approach was associated with a higher risk of permanent pacemaker (PPM) implantation (risk ratio: 1.44, 95% CI [1.07-1.95]; P=0.01) and longer operative times, but no significant differences in major clinical outcomes were found.

Key findings

  • The TS approach had a risk ratio of 1.44 for PPM implantation compared to the LA approach.
  • Patients undergoing TS had longer cardiopulmonary bypass and aortic cross-clamp times.
  • No significant differences were observed in mortality, infections, stroke, or renal failure between the two approaches.
  • Subgroup analysis showed higher PPM implantation and postoperative atrial fibrillation in the TS group.

Why it matters

Understanding the differences in outcomes between surgical approaches for mitral valve surgery is crucial for optimizing patient care. This analysis highlights the need for individualized surgical strategies based on patient-specific factors.

Source

PubMed · PMID 42585446

Published in Asian Cardiovasc Thorac Ann. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.